111 related articles for article (PubMed ID: 34655076)
21. Fetuin A as a new marker of inflammation in Hashimoto thyroiditis.
Muratli S; Uzunlulu M; Gonenli G; Oguz A; Isbilen B
Minerva Endocrinol; 2015 Mar; 40(1):9-14. PubMed ID: 24732714
[TBL] [Abstract][Full Text] [Related]
22. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
[TBL] [Abstract][Full Text] [Related]
23. The relationship between serum fetuin-A, cystatin-C levels, and microalbuminuria in patients with metabolic syndrome.
Huddam B; Azak A; Koçak G; Bayraktar N; Sezer S
J Clin Lab Anal; 2013 Jul; 27(4):317-22. PubMed ID: 23852792
[TBL] [Abstract][Full Text] [Related]
24. Determination of pentraxin 3 levels in diagnosis of appendicitis in children.
Ates U; Bahadir K; Ergun E; Gollu G; Durmaz M; Gunay F; Erguder I; Bingol-Kologlu M; Yagmurlu A; Dindar H; Cakmak M
Pediatr Int; 2020 May; 62(5):624-628. PubMed ID: 31886585
[TBL] [Abstract][Full Text] [Related]
25. Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases.
Menschikowski M; Hagelgans A; Fuessel S; Mareninova OA; Asatryan L; Wirth MP; Siegert G
Inflamm Res; 2013 Dec; 62(12):1063-72. PubMed ID: 24061501
[TBL] [Abstract][Full Text] [Related]
26. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
27. Serum procalcitonin levels in prostate cancer: A new biomarker?
Canat L; Atalay HA; Can O; Alkan İ; Ötünçtemur A
Urologia; 2018 May; 85(2):46-50. PubMed ID: 30043712
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy.
Kadoglou NP; Kottas G; Lampropoulos S; Vitta I; Liapis CD
Clin Drug Investig; 2014 Mar; 34(3):165-71. PubMed ID: 24307429
[TBL] [Abstract][Full Text] [Related]
29. Circulating levels of adiponectin, leptin, fetuin-A and retinol-binding protein in patients with tuberculosis: markers of metabolism and inflammation.
Keicho N; Matsushita I; Tanaka T; Shimbo T; Hang NT; Sakurada S; Kobayashi N; Hijikata M; Thuong PH; Lien LT
PLoS One; 2012; 7(6):e38703. PubMed ID: 22685600
[TBL] [Abstract][Full Text] [Related]
30. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Monda JM; Barry MJ; Oesterling JE
J Urol; 1994 May; 151(5):1291-5. PubMed ID: 7512660
[TBL] [Abstract][Full Text] [Related]
31. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
32. First trimester assessment of pentraxin-3 levels in women with primary unexplained recurrent pregnancy loss.
Ibrahim MI; Harb HM; Ellaithy MI; Elkabarity RH; Abdelgwad MH
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):37-41. PubMed ID: 22889492
[TBL] [Abstract][Full Text] [Related]
33. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
34. Fetuin-A Deficiency but Not Pentraxin 3, FGF-21, or Irisin, Predisposes to More Serious COVID-19 Course.
Kukla M; Menżyk T; Dembiński M; Winiarski M; Garlicki A; Bociąga-Jasik M; Skonieczna M; Hudy D; Maziarz B; Kuśnierz-Cabala B; Kapusta M; Skladany L; Grgurevic I; Mikolasevic I; Filipec-Kanizaj T; Wójcik-Bugajska M; Grodzicki T; Rogula T; Stygar D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680053
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study of Pentraxin 3 in diagnosing the severity and cardiovascular function of the children with sepsis].
Kang X; Zhu Y; Zhang X
Zhonghua Er Ke Za Zhi; 2015 Aug; 53(8):592-8. PubMed ID: 26717657
[TBL] [Abstract][Full Text] [Related]
36. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
37. Specifics of fetuin-A levels in distinct types of chronic heart failure.
Lichtenauer M; Wernly B; Paar V; Rohm I; Jung C; Yilmaz A; Hoppe UC; Schulze PC; Kretzschmar D; Pistulli R
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28213903
[TBL] [Abstract][Full Text] [Related]
38. C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris.
Borsky P; Fiala Z; Andrys C; Beranek M; Hamakova K; Kremlacek J; Malkova A; Svadlakova T; Krejsek J; Palicka V; Rehacek V; Kotingova L; Borska L
Physiol Res; 2021 Jul; 70(3):383-391. PubMed ID: 33982577
[TBL] [Abstract][Full Text] [Related]
39. The Role of Fetuin-A and Electrolytes in the Etiology of Sialolithiasis.
Demirhan H; Yıldız M; Çelebi ÖÖ; Baz Ş; İnal BB; Yiğit Ö
Otolaryngol Head Neck Surg; 2017 May; 156(5):840-843. PubMed ID: 28457217
[TBL] [Abstract][Full Text] [Related]
40. Systemic and local levels of fetuin-a in calcified mitral valves of rheumatic heart disease.
Mukhopadhyay S; Pandit BN; Saran RK; Mazumdar K; Yusuf J; Minhas HS; Trehan V; Tyagi S
J Heart Valve Dis; 2014 Jan; 23(1):55-65. PubMed ID: 24779329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
